{"id":"NCT00631371","sponsor":"Pfizer","briefTitle":"Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects","officialTitle":"Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2012-04","completion":"2015-04","firstPosted":"2008-03-07","resultsPosted":"2013-06-04","lastUpdate":"2016-04-27"},"enrollment":791,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Renal Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Torisel"]},{"type":"DRUG","name":"Temsirolimus","otherNames":[]},{"type":"DRUG","name":"Bevacizumab","otherNames":[]},{"type":"DRUG","name":"Interferon-Alfa 9MU","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"ACTIVE_COMPARATOR"}],"summary":"Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.","primaryOutcome":{"measure":"Progression-Free Survival (PFS): Independent-Assessment","timeFrame":"Baseline until disease progression, initiation of new anticancer treatment, or death, assessed every 8 weeks (up to cut-off date: 19 April 2012)","effectByArm":[{"arm":"Bevacizumab+Temsirolimus","deltaMin":9.1,"sd":null},{"arm":"Bevacizumab+ Interferon-Alfa","deltaMin":9.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":172,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Chile","Colombia","Czechia","France","Germany","Hong Kong","Hungary","India","Italy","Malaysia","Mexico","Netherlands","Poland","Portugal","Russia","Serbia","Singapore","Slovakia","South Africa","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["37146227","28410911","27238653","24297945"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3066K1-3311&StudyName=Study%20Comparing%20Bevacizumab%20+%20Temsirolimus%20vs.%20Bevacizumab%20+%20Interferon-Alfa%20In%20Advanced%20Renal%20Cell%20Carcinoma%20Subjects"]},"adverseEventsSummary":{"seriousAny":{"events":184,"n":393},"commonTop":["Proteinuria","Pyrexia","Decreased appetite","Hypertension","Fatigue"]}}